# AEye, Inc.: financial statements, quarterly

LIDR · Nasdaq · CIK 1818644 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lidr.md) · [Financials](/companies/lidr/financials.md) · [Filings](/companies/lidr/filings.md) · [Insiders](/companies/lidr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lidr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.2](/filings/0001437749-24-035017.md) | [0.1 d](/filings/0001437749-25-004906.md) | [0.0](/filings/0001437749-25-015868.md) | [0.0](/filings/0001437749-25-025747.md) | [0.1](/filings/0001437749-25-033677.md) | [0.0 d](/filings/0001437749-26-008858.md) | [0.1](/filings/0001437749-26-017094.md) | [0.0](/filings/0001437749-26-026354.md) | [0.1](/filings/0001437749-25-033677.md) | [0.1 d](/filings/0001437749-26-008858.md) | [0.1](/filings/0001437749-26-017094.md) | [0.2](/filings/0001437749-26-026354.md) |
| Cost of revenue | $m | [4.5](/filings/0001437749-24-035017.md) | [6.7 d](/filings/0001437749-25-004906.md) | [0.3](/filings/0001437749-25-015868.md) | [0.2](/filings/0001437749-25-025747.md) | [0.3](/filings/0001437749-25-033677.md) | [0.0 d](/filings/0001437749-26-008858.md) | [0.1](/filings/0001437749-26-017094.md) | [0.1](/filings/0001437749-26-026354.md) | [0.1](/filings/0001437749-25-033677.md) | [0.2 d](/filings/0001437749-26-008858.md) | [0.2](/filings/0001437749-26-017094.md) | [0.4](/filings/0001437749-26-026354.md) |
| Gross profit | $m | [(4.3)](/filings/0001437749-24-035017.md) | [(6.6) d](/filings/0001437749-25-004906.md) | [(0.2)](/filings/0001437749-25-015868.md) | [(0.1)](/filings/0001437749-25-025747.md) | [(0.2)](/filings/0001437749-25-033677.md) | [(0.0) d](/filings/0001437749-26-008858.md) | [(0.0)](/filings/0001437749-26-017094.md) | [(0.1)](/filings/0001437749-26-026354.md) | [(0.1)](/filings/0001437749-25-033677.md) | [(0.2) d](/filings/0001437749-26-008858.md) | [(0.1)](/filings/0001437749-26-017094.md) | [(0.2)](/filings/0001437749-26-026354.md) |
| Research and development | $m | [5.7](/filings/0001437749-24-035017.md) | [5.2 d](/filings/0001437749-25-004906.md) | [4.5](/filings/0001437749-25-015868.md) | [3.8](/filings/0001437749-25-025747.md) | [3.8](/filings/0001437749-25-033677.md) | [4.3 d](/filings/0001437749-26-008858.md) | [3.5](/filings/0001437749-26-017094.md) | [3.7](/filings/0001437749-26-026354.md) | [3.1](/filings/0001437749-25-033677.md) | [3.7 d](/filings/0001437749-26-008858.md) | [3.8](/filings/0001437749-26-017094.md) | [4.7](/filings/0001437749-26-026354.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(17.2)](/filings/0001437749-24-035017.md) | [(28.5) d](/filings/0001437749-25-004906.md) | [(10.7)](/filings/0001437749-25-015868.md) | [(8.3)](/filings/0001437749-25-025747.md) | [(7.8)](/filings/0001437749-25-033677.md) | [(9.0) d](/filings/0001437749-26-008858.md) | [(6.8)](/filings/0001437749-26-017094.md) | [(8.7)](/filings/0001437749-26-026354.md) | [(7.8)](/filings/0001437749-25-033677.md) | [(8.4) d](/filings/0001437749-26-008858.md) | [(9.0)](/filings/0001437749-26-017094.md) | [(10.8)](/filings/0001437749-26-026354.md) |
| Income tax | $m | [0.0](/filings/0001437749-24-035017.md) | [0.0 d](/filings/0001437749-25-004906.md) | [0.0](/filings/0001437749-25-015868.md) | [0.0](/filings/0001437749-24-025210.md) | [0.0](/filings/0001437749-24-035017.md) | [(0.0) d](/filings/0001437749-26-008858.md) | [0.0](/filings/0001437749-26-017094.md) | [0.0](/filings/0001437749-26-026354.md) | [0.0 d](/filings/0001437749-25-033677.md) | [0.0 d](/filings/0001437749-26-008858.md) | [0.0](/filings/0001437749-26-017094.md) | [0.0](/filings/0001437749-26-026354.md) |
| Net income | $m | [(17.0)](/filings/0001437749-24-035017.md) | [(27.8) d](/filings/0001437749-25-004906.md) | [(10.2)](/filings/0001437749-25-033677.md) | [(8.0)](/filings/0001437749-25-033677.md) | [(8.7)](/filings/0001437749-25-033677.md) | [(8.5) d](/filings/0001437749-26-008858.md) | [(8.0)](/filings/0001437749-26-026354.md) | [(9.3)](/filings/0001437749-26-026354.md) | [(9.3)](/filings/0001437749-25-033677.md) | [(7.3) d](/filings/0001437749-26-008858.md) | [(8.3)](/filings/0001437749-26-026354.md) | [(10.0)](/filings/0001437749-26-026354.md) |
| Diluted EPS | $ per share | [(0.09)](/filings/0001818644-23-000014.md) | not reported | [(1.61)](/filings/0001818644-24-000006.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(2.78)](/filings/0001437749-24-035017.md) | not reported | [(1.61)](/filings/0001437749-25-015868.md) | [(1.16)](/filings/0001437749-25-025747.md) | [(1.01)](/filings/0001437749-25-033677.md) | not reported | [(0.46)](/filings/0001437749-26-017094.md) | [(0.48)](/filings/0001437749-26-026354.md) | [(0.30)](/filings/0001437749-25-033677.md) | not reported | [(0.18)](/filings/0001437749-26-017094.md) | [(0.22)](/filings/0001437749-26-026354.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [37.1](/filings/0001818644-23-000014.md) | [16.9](/filings/0001437749-25-004906.md) | [9.5](/filings/0001818644-24-000006.md) | [11.2](/filings/0001437749-24-025210.md) | [5.9](/filings/0001437749-24-035017.md) | [10.3](/filings/0001437749-26-008858.md) | [5.3](/filings/0001437749-25-015868.md) | [2.4](/filings/0001437749-25-025747.md) | [43.0](/filings/0001437749-25-033677.md) | [43.4](/filings/0001437749-26-026354.md) | [45.2](/filings/0001437749-26-017094.md) | [11.2](/filings/0001437749-26-026354.md) |
| Current assets | $m | [55.5](/filings/0001818644-23-000014.md) | [39.8](/filings/0001437749-25-004906.md) | [31.3](/filings/0001818644-24-000006.md) | [30.2](/filings/0001437749-24-025210.md) | [24.3](/filings/0001437749-24-035017.md) | [25.2](/filings/0001437749-26-008858.md) | [27.0](/filings/0001437749-25-015868.md) | [20.4](/filings/0001437749-25-025747.md) | [86.2](/filings/0001437749-25-033677.md) | [89.6](/filings/0001437749-26-026354.md) | [79.7](/filings/0001437749-26-017094.md) | [74.3](/filings/0001437749-26-026354.md) |
| Total assets | $m | [80.9](/filings/0001818644-23-000014.md) | [54.3](/filings/0001437749-25-004906.md) | [45.4](/filings/0001818644-24-000006.md) | [44.0](/filings/0001437749-24-025210.md) | [26.4](/filings/0001437749-24-035017.md) | [27.1](/filings/0001437749-26-008858.md) | [28.8](/filings/0001437749-25-015868.md) | [22.1](/filings/0001437749-25-025747.md) | [87.5](/filings/0001437749-25-033677.md) | [90.9](/filings/0001437749-26-026354.md) | [82.1](/filings/0001437749-26-017094.md) | [76.6](/filings/0001437749-26-026354.md) |
| Current liabilities | $m | [12.0](/filings/0001818644-23-000014.md) | [10.0](/filings/0001437749-25-004906.md) | [9.0](/filings/0001818644-24-000006.md) | [8.9](/filings/0001437749-24-025210.md) | [10.7](/filings/0001437749-24-035017.md) | [11.3](/filings/0001437749-26-008858.md) | [10.8](/filings/0001437749-25-015868.md) | [10.6](/filings/0001437749-25-025747.md) | [8.1](/filings/0001437749-25-033677.md) | [8.6](/filings/0001437749-26-026354.md) | [6.2](/filings/0001437749-26-017094.md) | [6.9](/filings/0001437749-26-026354.md) |
| Total liabilities | $m | [27.5](/filings/0001818644-23-000014.md) | [25.3](/filings/0001437749-25-004906.md) | [23.5](/filings/0001818644-24-000006.md) | [23.2](/filings/0001437749-24-025210.md) | [11.5](/filings/0001437749-24-035017.md) | [12.0](/filings/0001437749-26-008858.md) | [11.8](/filings/0001437749-25-015868.md) | [11.9](/filings/0001437749-25-025747.md) | [9.4](/filings/0001437749-25-033677.md) | [9.6](/filings/0001437749-26-026354.md) | [7.8](/filings/0001437749-26-017094.md) | [8.3](/filings/0001437749-26-026354.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [53.3](/filings/0001437749-24-035017.md) | [29.0](/filings/0001437749-26-008858.md) | [21.9](/filings/0001437749-25-033677.md) | [20.8](/filings/0001437749-25-033677.md) | [14.9](/filings/0001437749-25-033677.md) | [15.1](/filings/0001437749-26-026354.md) | [17.0](/filings/0001437749-26-026354.md) | [10.2](/filings/0001437749-26-026354.md) | [78.2](/filings/0001437749-25-033677.md) | [81.3](/filings/0001437749-26-026354.md) | [74.2](/filings/0001437749-26-026354.md) | [68.3](/filings/0001437749-26-026354.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(9,063) d](/filings/0001437749-24-035017.md) | [(9,217) d](/filings/0001437749-25-004906.md) | [(7,885)](/filings/0001437749-25-015868.md) | [(6,356) d](/filings/0001437749-25-025747.md) | [(7,573) d](/filings/0001437749-25-033677.md) | [(4,806) d](/filings/0001437749-26-008858.md) | [(7,803)](/filings/0001437749-26-017094.md) | [(6,355) d](/filings/0001437749-26-026354.md) | [(6,089) d](/filings/0001437749-25-033677.md) | [(7,530) d](/filings/0001437749-26-008858.md) | [(8,555)](/filings/0001437749-26-017094.md) | [(7,287) d](/filings/0001437749-26-026354.md) |
| Capital expenditure | $k | [613 d](/filings/0001437749-24-035017.md) | [530 d](/filings/0001437749-25-004906.md) | [87.0](/filings/0001437749-25-015868.md) | [147 d](/filings/0001437749-25-025747.md) | [186 d](/filings/0001437749-25-033677.md) | [66.0 d](/filings/0001437749-26-008858.md) | [6.0](/filings/0001437749-26-017094.md) | [8.0 d](/filings/0001437749-26-026354.md) | [38.0 d](/filings/0001437749-25-033677.md) | [57.0 d](/filings/0001437749-26-008858.md) | [187](/filings/0001437749-26-017094.md) | [132 d](/filings/0001437749-26-026354.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [159](/filings/0001818644-23-000014.md) | [5.5](/filings/0001818644-24-000006.md) | [5.9](/filings/0001437749-24-025210.md) | [6.1](/filings/0001437749-24-035017.md) | [6.4](/filings/0001437749-25-015868.md) | [6.9](/filings/0001437749-25-025747.md) | [8.6](/filings/0001437749-25-033677.md) | [17.4](/filings/0001437749-26-017094.md) | [19.1](/filings/0001437749-26-026354.md) | [31.3](/filings/0001437749-25-033677.md) | [45.2](/filings/0001437749-26-017094.md) | [45.9](/filings/0001437749-26-026354.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 46,488,312 at 2026-08-04, from the cover of the [10-Q filed 2026-08-06](/filings/0001437749-26-026354.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.